Literature DB >> 16480279

A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.

Andrew J Harvey1, Jonathan B Baell, Nathan Toovey, Daniel Homerick, Heike Wulff.   

Abstract

The voltage-gated potassium channel Kv1.3 constitutes an attractive target for the selective suppression of effector memory T cells in autoimmune diseases. We have previously reported the natural product khellinone, 1a, as a versatile lead molecule and identified two new classes of Kv1.3 blockers: (i) chalcone derivatives of khellinone, and (ii) khellinone dimers linked through the 6-position. Here we describe the multiple parallel synthesis of a new class of khellinone derivatives selectively alkylated at either the 4- or 7-position via the phenolic OH and show that several chloro, bromo, methoxy, and nitro substituted benzyl derivatives inhibit Kv1.3 with submicromolar potencies. Representative examples of the most potent compounds from each subclass, 11m (5-acetyl-4-(4'-chloro)benzyloxy-6-hydroxy-7-methoxybenzofuran) and 14m (5-acetyl-7-(4'-bromo)benzyloxy-6-hydroxy-4-methoxybenzofuran), block Kv1.3 with EC50 values of 480 and 400 nM, respectively. Both compounds exhibit moderate selectivity over other Kv1-family channels and HERG, are not cytotoxic, and suppress human T cell proliferation at low micromolar concentrations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480279     DOI: 10.1021/jm050839v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.

Authors:  Pavel I Zimin; Bojan Garic; Silke B Bodendiek; Cédrick Mahieux; Heike Wulff; Boris S Zhorov
Journal:  Mol Pharmacol       Date:  2010-07-02       Impact factor: 4.436

2.  4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.

Authors:  Silke B Bodendiek; Cédrick Mahieux; Wolfram Hänsel; Heike Wulff
Journal:  Eur J Med Chem       Date:  2008-11-05       Impact factor: 6.514

Review 3.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 4.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

5.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

Review 6.  Use of Kv1.3 blockers for inflammatory skin conditions.

Authors:  W Nguyen; B L Howard; D S Neale; P E Thompson; P J White; H Wulff; D T Manallack
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

7.  Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.

Authors:  Heike Wulff
Journal:  Expert Opin Ther Pat       Date:  2010-10-18       Impact factor: 6.674

Review 8.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 9.  The functional network of ion channels in T lymphocytes.

Authors:  Michael D Cahalan; K George Chandy
Journal:  Immunol Rev       Date:  2009-09       Impact factor: 12.988

10.  Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.

Authors:  William Nguyen; Brittany L Howard; David P Jenkins; Heike Wulff; Philip E Thompson; David T Manallack
Journal:  Bioorg Med Chem Lett       Date:  2012-09-29       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.